Kornimate/medical-research-clean huggingface dataset:
photobiomodulation therapy and transcutaneous electrical nerve stimulation on chronic neck pain patients

Conditions: Chronic Neck Pain

Summary: this study evaluates the efficacy isolated and combinaded of photobiomodulation therapy with low level laser therapy and the transcutaneous electrical nerve stimulation.

non-specific chronic neck pain patients will be treated with low-level laser therapy and/or trancutaneous electricam nerve stimulation. they will receive 10 sessions of treatment. before and after the treatment physical measures and psychosocial factors will be evaluted to verificy the efficay these electrophysical agents.

Eligibility criteria:
inclusion criteria: * patients with non-specific chronic neck pain, defined as pain or discomfort in the posterior cervical region between the superior nuchal line and the first thoracic spinous process and / or shoulder girdle; * neck pain for at least 3 months; * neck disability index (ndi) score of 5 points or higher; * numeric rating scale (nrs) score of 3 or higher to pain intensity; * aged between 18 and 65 years; * men and women exclusion criteria: * neck pain associated with nerve root compromise (measured by clinical examination of dermatomes, myotomes and reflexes); * previous spinal surgery; * patients treated with physical therapy for neck pain in the last 3 months previous the study; * severe spinal disorders such as fractures, tumors, inflammatory and infectious diseases; * any contraindication to low level laser therapy or transcutaneous electrical nerve stimulation; * rheumatic, metabolic, neurological or cardiopulmonary diseases; * patients who require artificial cardiac pacemakers; * skin diseases, mainly at the current application site; * tumors or cancer historic in the last 5 years; * pregnancy; * if the patient started any physical activity in the last 2 weeks.

Keywords: electrophysical agents low-level laser therapy tens neck pain chronic pain
sargramostim after bone marrow transplantation in treating patients with myelodysplastic syndrome

Conditions: Leukemia; Myelodysplastic Syndromes; Myelodysplastic/Myeloproliferative Diseases

Summary: rationale: colony-stimulating factors, such as sargramostim, may increase the number of immune cells found in bone marrow or peripheral blood. purpose: phase ii trial to study the effectiveness of sargramostim after bone marrow transplantation in treating patients who have myelodysplastic syndrome.

objectives: * determine the effect of sargramostim (gm-csf) on the progression-free 1-year survival of patients with myelodysplastic syndrome who have undergone t-cell-depleted cd34+ augmented allogeneic bone marrow transplantation. outline: all patients receive elutriated, cd34+ stem cell augmented donor bone marrow according to another protocol on day 0. patients receive sargramostim (gm-csf) subcutaneously on days 5-60. patients are followed on days 120, 180, 360 and periodically thereafter. projected accrual: a total of 45 patients will be accrued for this study within 3-4 years.

Eligibility criteria:
disease characteristics: * cytologically proven myelodysplastic syndrome (mds) of one of the following types: * refractory anemia with excess blasts (raeb) * raeb in transformation * chronic myelomonocytic leukemia * mds with multiple chromosomal abnormalities * mds with life threatening cytopenias in at least 2 cell lines * platelet count \< 30,000/mm\^3 or * absolute neutrophil count no greater than 1,000/mm\^3 or * anemia requiring transfusion support * leukemia out of mds (meet any of above requirements, but greater than 30% blasts in marrow) * no acute leukemia * medically eligible for bone marrow transplant according to standard operating procedure of the sidney kimmel cancer center at johns hopkins blood and bone marrow transplant patient characteristics: age: * 18 to 65 performance status: * ecog 0-1 life expectancy: * not specified hematopoietic: * see disease characteristics hepatic: * not specified renal: * not specified other: * no prior acute allergic reactions to sargramostim (gm-csf) * not pregnant * fertile patients must use effective contraception prior concurrent therapy: biologic therapy: * not specified chemotherapy: * not specified endocrine therapy: * not specified radiotherapy: * not specified surgery: * not specified

Keywords: refractory anemia with excess blasts refractory anemia with excess blasts in transformation chronic myelomonocytic leukemia de novo myelodysplastic syndromes previously treated myelodysplastic syndromes secondary myelodysplastic syndromes refractory cytopenia with multilineage dysplasia atypical chronic myeloid leukemia myelodysplastic/myeloproliferative disease, unclassifiable
quality of life and decisional regret in patients affected by acoustic neuroma

Conditions: Quality of Life Outcomes; Acoustic Schwannoma

Summary: italian translation and validation study of two different questionnaire (vsqol and drs) about quality of life in patient with acoustic schwannoma.


Eligibility criteria:
inclusion criteria: * patient with sporadic acoustic neuroma in follow-up with wait and scan protocol or treated with microsurgical resection with any approach exclusion criteria: * patient with nf2 * patient previuosly treated with rt in the head and neck district * patient with pre-treatment facial palsy ipsi and controlateral * patient non native italian speakers * patient with major mental illness already existing before the acoustic neuroma diagnosis * patient with neurological issues such as chronic migraine or postural instability already existing before the acoustic neuroma diagnosis
effect of sodium glucose co-tansporter 2 inhibitors (sglt2i) on inflammatory and oxidative stress markers level in heart failure patients

Conditions: Heart Failure

Summary: the aim of this study is to explore the effect of sglt2i on the levels of cardiac biomarkers, inflammatory and stress markers in egyptian heart failure patients to provide a better understanding of mechanism that might assist in tailoring treatment strategies in patients with various forms of hf especially in egyptian population. also understand how biomarkers may be employed to predict risk in patients receiving sglt2i or identification of those who may derive the most benefit from sglt2i in the means of individualized medicine.


Eligibility criteria:
inclusion criteria: 1. patients aged more than 18 years old. 2. patients are with cardiac function was graded as ii-iv by the new york heart association (nyha) 3. patients are on standard therapy for management of hf (according to aha/acc/hfsa guideline for the management of heart failure2022)21 such as: * acei (angiotensin converting enzyme inhibitor) * arb (angiotensin receptor blocker) * arni in place of acei or arb * beta blocker * (mra) mineralocorticoid receptor antagonists * diuretics as needed. 4. all patients signed the informed consent. exclusion criteria: 1. patients suffering from conditions like acute cvs illness and severe sepsis that raise inflammatory markers and may lead to cardiac dysfunction as opposed to heart failure. 2. patients with various cardiac conditions, such as severe congenital heart disease, myocarditis, and valvular heart disease. 3. female patients during pregnancy or lactation 4. individuals suffering from a malignant tumor, hyperfunctioning thyroid, multiple organ failure, or significantly reduced kidney function (egfr \<20 ml/min/1.73 m²). 5. individuals suffering from verbal communication disorders or psychic cognitive impairment.
treatment of infertility in women with polycystic ovary syndrome

Conditions: Polycystic Ovary Syndrome; Infertility; Pregnancy

Summary: polycystic ovary syndrome (pcos) is a common endocrine disorder affecting up to 10% of women. the primary symptoms of pcos are menstrual irregularities, increased body and facial hair, acne, and infertility. this study will test a combination of medications in women with pcos to determine which works best to overcome infertility.

pcos is characterized by excess circulating androgen levels and chronic anovulation. the fundamental pathophysiologic defect is unknown, but pcos is characterized by insulin resistance and compensatory hyperinsulinemia. improvements in insulin sensitivity in pcos women, either through lifestyle changes or through pharmaceutical intervention, have consistently resulted in a marked improvement in the reproductive and metabolic abnormalities in pcos. resumption of ovulation occurs in up to 70% of women treated for pcos. this study will evaluate the safety and effectiveness of clomiphene citrate and metformin xr in achieving a successful pregnancy in infertile pcos women. women with pcos who are seeking pregnancy will be enrolled in this study. women will be randomized to one of three different treatment arms: a) metformin xr 1000 mg twice/day; b) clomiphene citrate 50 mg every day for 5 days (day 3-7 of cycle); or c) metformin xr 1000 mg twice/day with clomiphene citrate 50 mg/day for 5 days (day 3-7 of cycle). women will continue on study medications for 30 weeks, 6 treatment cycles, or until they become pregnant. progesterone levels will be drawn weekly to monitor ovulation.

Eligibility criteria:
inclusion criteria * eight or fewer menstrual cycles in the past year or intermenstrual periods of 45 days or longer * elevated testosterone level * good general health * sperm concentration in partner of 20 million/ml or greater * ability to have intercourse 2-3 times per week * one functional fallopian tube and normal uterine cavity
precision cell immunotherapy combined with chemotherapy in advanced gastric cancer

Conditions: Precision Cell Immunotherapy; Chemotherapy; Advanced Malignancies

Summary: objectives: to evaluate the safety and effectiveness of cell therapy using precision cell immunotherapy to treat advanced gastric cancer. eligibility: individuals greater than or equal to 18 years of age and less than or equal to 65 years of age who have been diagnosed with advanced gastric cancer.

a total of 40 patients may be enrolled over a period of 1-2 years.

Eligibility criteria:
inclusion criteria: * age 18\~65 years old, male or female; * life expectancy≥6 months; * ecog score: 0-3; * advanced malignancies (gastric cancer) were diagnosed by pathological or clinical physicians; * enough venous channel, no other contraindications to the separation and collection of white blood cells; * laboratory examination: white blood cell≥3 x 10\*9/l, blood platelet count≥60 x 10\*/l, hemoglobin≥85g/l; lymphocyte count≥15%, total bilirubin≤100 mol/l; alt and ast less than five times of the normal level; serum creatinine less than 1.5 times of the normal level; * signed informed consent; * women of child-bearing age must have evidence of negative pregnancy test and be willing to practice birth control after 2 weeks following the cells transfusion. exclusion criteria: * expected overall survival \< 6 months; * patients with uncontrolled hypertension (\>160/95mmhg), unstable coronary disease (uncontrolled arrhythmias, unstable angina, decompensated congestive heart failure (\> class ii, nyha), or myocardial infarction within 6 months; * other serious diseases: nervous, mental disorders, immune regulatory diseases, metabolic diseases, infectious diseases, etc; * other drugs, or other biological treatment,chemotherapy or radiotherapy are performed within a month; * unable or unwilling to provide informed consent, or fail to comply with the test requirements.

Keywords: precision cell immunotherapy chemotherapy advanced malignancies
electronic tools to assist with identification of and counseling for overweight patients

Conditions: Overweight

Summary: the purpose of this study is to design and assess the impact of an electronic alert and tool set to assist with physician identification and counseling of overweight patients.

overweight adults (body mass index \[bmi\] 25-29.9) are at high risk for developing obesity, but rates of physician identification and counseling of overweight adults are low. alerts and tools embedded in the electronic medical record have shown promise in enhancing quality improvement efforts. our aim is to design and assess the impact of an electronic alert and tool set to assist with identification and counseling of overweight patients with a bmi 27-29.9. although the category of overweight patients spans bmi 25-29.9, we are including only patients with bmi 27-29.9 in order to focus resources on the most at-risk pre-obese population. we will develop a tool set including the following components: automatic calculation of bmi, alert for overweight status, counseling template for weight loss goal-setting, linkage to referral options, and access to relevant patient handouts. physicians in the northwestern memorial faculty foundation general internal medicine (nmff gim) practice who consent to participate in the study will be randomized into two groups, with one group of physicians receiving access to these tools. the other group of physicians will continue to provide their usual care for overweight patients. outcome measures will include the following: tool usage; documentation of overweight in the problem list, encounter diagnosis, or note text; counseling for overweight and documentation of specific behavioral goals. measures will be obtained via retrospective chart review.

Eligibility criteria:
inclusion criteria (physicians): * consenting physicians from the northwestern memorial general internal medicine (nmff gim) practice exclusion criteria (physicians): * study investigators will be excluded from participation (dr. david baker, dr. joyce tang) inclusion criteria (patients): * adults ages 18-65 seen at the nmff gim who are patients of consenting physicians * have at least one appointment at the nmff gim clinic between 9/1/09-2/28/10 * body mass index (bmi) 27-29.9 at one or more visits between 9/1/09-2/28/10 exclusion criteria (patients): * patients without at least one recorded height measurement from any prior visit or without weight information from a visit within the 6 month target window will be excluded due to inability to calculate bmi.

Keywords: overweight diagnosis counseling medical records systems, computerized
autonomic nervous system, fatigue and intolerance to physical training, and overtraining in high-level athletes

Conditions: Athletes; Training; Fatigue

Summary: sports training aims to enhance an athlete's performance (overcompensation). to do that, the athlete must go through periods of fatigue and lower performance (overreaching). when the training plan is balanced, this fatigue is short and reversible.if the training load is too heavy or if recuperation periods are too short, it can lead to persistence fatigue that may only be reversible in the long term. this state of fatigue is part of the broader clinical picture of overtraining, which includes stark changes in performance as well as mood and sleep disorders. many prediction and characterization methods based on biological markers have been evaluated, but they have not been put into practice in sports training due to obstacles such as reliability, interindividual variability and high costs. this study aims to evaluate a new approach based on the variability of an individual's heart rate (rr variability), which is a way of measuring autonomic nervous system (asn) activity. it is non-invasive, low-cost, and has already proven useful in athlete health monitoring.

the investigators propose to describe the variation of these ans regulation factors over a full year, in a population of high-level athletes, in order to measure changes in regulation which may be predictive of potential fatigue and intolerance to physical training, if such a syndrome came to be observed among the study group.

Eligibility criteria:
inclusion criteria: * high-level athlete, enrolled in a ministry-recognized pôle * participant signed the informed consent form exclusion criteria: * confirmed current overtraining syndrome * known pregnancy on inclusion * athlete using cardio-inhibitor or cardio-accelerator drugs

Keywords: high-level athlete ans activity overtraining
4th ventricular compression technique on anxiety

Conditions: Healthy

Summary: determinate the effects of the technique of 4th ventricle in college students with anxiety, applying the technique one time per week during three weeks.

the anxiety is a warning sign that makes it possible for the individual to defend themselves and protect themselves from threats. this is considered a natural and necessary reaction for self-preservation. however, when it appears persistently, exaggeratedly or disproportionately in relation to a stimulus, the following are considered: pathological anxiety. the compression of the fourth ventricle (cv4) is one of the most well-known procedures in the practice of cranial manipulation. it is also one of the most clinically tested techniques and has been postulated to be associated with decreased sympathetic tone. therefore, this was the chosen technique, as it significantly affects the relaxation of the sns tonus and, thereafter, anxiety.

Eligibility criteria:
inclusion criteria: * ages between 18 and 25 years old; * be a college/university student; * not have knowledge of the technique used; * achieve a 20 plus score on the state-trait anxiety inventory questionnaire. exclusion criteria: * use of pharmacological therapy for psychological disorders; * presence of conditions that prevent or contraindicate the technique, including tumors, fractures, dislocations, vertebrobasilar insufficiency, bone diseases, neurological diseases, fever, skin diseases, cardiovascular diseases, psychiatric diseases, increased intracranial pressure. * surgeries or traumas in the specific areas of the technique; * pregnancy; * osteopathic treatments or other manual therapies aimed at reducing anxiety; * evident postural alteration or deformity of the thoracic cage.

Keywords: anxiety college students cv4 osteopathic treatment
tocilizumab for the treatment of refractory behcet's uveitis

Conditions: Behcet Syndrome; Uveitis

Summary: the aim of this single-center prospective study is to evaluate the efficacy and safety of tocilizumab (tcz), humanized monoclonal antibody against il-6receptor, in the treatment of refractory uveitis of behçet's disease (bdu), to verify its effects on decreasing the dose of cortical steroids, and to determine whether it can reduce bdu recurrence.

uveitis of behçet's disease (bdu) is the most common form of ocular manifestations, which is also the leading cause of irreversible visual impairment. the aim of the study is to improve treatment strategy of the disease as well as to reduce blindness. tocilizumab (tcz) is a humanized antibody against il-6 receptor, clinical trials on non-infectious uveitis and retrospective study on bdu has obtained expected results. this single-center prospective study is to evaluate the efficacy and safety of tcz in the treatment of refractory bdu, to verify its effects on decreasing the dose of corticosteroids, and to determine whether it can reduce bdu recurrence.the investigators aim to enroll nine refractory bdu patients with acute onset uveitis, with difficulty tapering corticosteroids while being treated with at least one of the commonly used immunosuppressants. all participants will receive tcz , oral corticosteroids and immunosuppressants will remain unchanged, intraocular injection will be avoided. during monthly follow-up, the investigators will measure and record intraocular inflammation status，as well as extraocular manifestations and the acute-phase reactants. the participants will continue to receive tcz for six months, the primary end point is the efficacy four weeks after first dose of tcz, secondary end points other than intraocular inflammation will be achieved on each follow-up visit, as quality of life improvements, side effects, recurrence of uveitis, and corticosteroids-tapering effects. on statistical analysis, the self-control treatment efficiency and recurrence rate difference will be determined using t-test of paired samples at a significance level of 0.05(2-sided). to ensure the interest of the participants, the study has been reviewed by the pumch ethics committee, and drug clinical research liability insurance was prepared.

Eligibility criteria:
inclusion criteria: * all participants fulfill the the proposed international criteria for bd, either isg criteria(1990) or icbd criteria(2013). * all participants present with refractory bdu , acute onset uveitis, either posterior segment involvement or panuveitis, with difficulty tapering corticosteroids while being treated with at least one of the commonly used immunosuppressants, without severe extraocular manifestations. exclusion criteria: * patients with impaired hepatic and renal function, other severe ocular diseases, active tuberculosis, viral hepatitis, malignancy, pregnancy will be excluded.

Keywords: tocilizumab refractory uveitis
levetiracetam (keppra) to improve chronic aphasia in post-stroke patients.

Conditions: Aphasia; Stroke

Summary: the study investigates the possibility that levetiracetam may improve the symptoms of chronic post-stroke aphasia.

in the study, 50 post-stroke subjects with aphasia will take levetiracetam and we will evaluate their speech, language, and memory in an abab design.

Eligibility criteria:
inclusion criteria: * stroke * aphasia * can give consent exclusion criteria: * renal failure * pregnancy * other neurological condition

Keywords: aphasia stroke
education intervention on vaccination adherence among inflammatory bowel disease (ibd) patients

Conditions: Crohn Disease (CD); Ulcerative Colitis (UC); Indeterminate Colitis

Summary: a retrospective chart review and a six-month prospective outcome analysis aimed to evaluate the efficacy of a vaccination education intervention and vaccination adherence among ibd patients at weill-cornell medical center. it is hypothesized that a general vaccination education campaign will improve vaccination adherence rates for all ibd patients. secondarily, it is hypothesized that an human papilloma virus (hpv) vaccination intervention targeted at high-risk ibd patients will increase vaccination adherence among these patients.


Eligibility criteria:
inclusion criteria: * patient at weill-cornell medical center with an in-person or virtual appointment between march 1 - august 30, 2021. * documentation of an ibd diagnosis (cd, uc, ic). exclusion criteria: * no documentation of an ibd diagnosis. * pregnant or breastfeeding. * no scheduled appointment between march 1-august 30, 2021.

Keywords: vaccine hpv vaccination ibd inflammatory bowel diseases uc cd